Stopping Fingolimod – Gilenya – for Pregnancy Raises Relapse Risk

Stopping Fingolimod – Gilenya – for Pregnancy Raises Relapse Risk

306987

Stopping Fingolimod – Gilenya – for Pregnancy Raises Relapse Risk

Women with relapsing-remitting multiple sclerosis (MS) who suspend their use of fingolimod — sold as Gilenya, among others — to conceive or during the early stages of pregnancy have a significantly higher risk of relapse during and after pregnancy, a new study finds. Stopping fingolimod resulted in a greater proportion of women developing new or enlarging lesions, as well as lesions with active inflammation, the results showed. In fact, 22% of the participants experienced relapses…

You must be logged in to read/download the full post.